The Lewy Body Dementia Association & Acadia Pharmaceuticals to Release Educational Version of the Highly Acclaimed Robin Will...
October 14 2020 - 4:05PM
Business Wire
The Lewy Body Dementia Association (LBDA) and Acadia
Pharmaceuticals Inc. (Nasdaq: ACAD) announced today an exclusive
partnership on the production and release of a disease education
adaptation of the new film Robin’s Wish©, a documentary detailing
the late actor Robin Williams’ courageous battle with the
neurodegenerative disorder, Lewy body dementia (LBD).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20201014005922/en/
The film, SPARK - Robin Williams and his Battle with Lewy Body
Dementia©, will go beyond describing LBD through the lens of
Williams’ personal experience and delve into the neurobiology of
the disease and associated symptoms to help educate the medical
community on the second most common form of degenerative dementia.
Lewy body dementia is also the most misdiagnosed dementia, and
healthcare provider education is needed to enable early
recognition, diagnosis and treatment.
While the full-length film is available on demand and via
digital channels, the adaptation, will be available to major
academic research institutions and universities as part of
educational programming and outreach to the healthcare
professionals, the LBD community and general public. The film will
be available starting in late October.
“Robin Williams unknowingly battled LBD and unfortunately, he is
not alone. This version of the documentary will not only raise
awareness of Lewy body dementia, but reinforce the importance of
early symptom recognition, diagnosis and effective management of
this devastating disease, and can serve as a key element in our
educational offering,” said Todd Graham, Executive Director, Lewy
Body Dementia Association.
Approximately 8 million people in the United States are living
with dementia, although only half are diagnosed with the
condition.1,2,3 In addition to cognitive decline, neuropsychiatric
symptoms, including hallucinations, delusions and changes in
behavior, are also common. Lewy body dementia affects approximately
1.4 million people and their families in the United States
alone.4
“The use of scientific storytelling is an important opportunity
to increase knowledge within the medical community on the need for
better diagnostic and disease management solutions. Our goal is to
ensure people struggling with LBD get the comprehensive support
they need,” said Ponni Subbiah, M.D., M.P.H., Senior Vice
President, Global Head of Medical Affairs and Chief Medical Officer
at Acadia. “We are honored to partner with the LBDA and share a
commitment to shine a light on the challenges that people with Lewy
body dementia and their caregivers face.”
About Lewy Body Dementia Association
The Lewy Body Dementia Association (LBDA) is the nation’s
leading authority on Lewy body dementias (LBD) and is dedicated to
continuous outreach, education, research, and support for those
affected with LBD and their families. LBD is a progressive brain
disease that affects thinking, movement, behavior, and impacts 1.4
million people in the United States.
About Acadia Pharmaceuticals
Acadia is trailblazing breakthroughs in neuroscience to elevate
life through science. For more than 25 years we have been working
at the forefront of healthcare to bring vital solutions to people
who need them most. We developed and commercialize the first and
only approved therapy for hallucinations and delusions associated
with Parkinson’s disease psychosis. Our late-stage development
efforts are focused on dementia-related psychosis, negative
symptoms of schizophrenia and Rett syndrome, and in early-stage
clinical research we are exploring novel approaches to pain
management, cognition and neuropsychiatric symptoms in central
nervous system disorders. For more information, visit us at
www.acadia-pharm.com and follow us on LinkedIn.
References
1 Plassman, BL Langa KM, Fisher GG, et al. Prevalence of
dementia in the United States: the aging, demographics, and memory
study. Neuroepidemiology. 2007;29(1-2):125-132. 2 Goodman RA,
Lochner KA, Thambisetty M, Wingo TS, Posner SF, Ling SM. Prevalence
of dementia subtypes in United States Medicare fee-for-service
beneficiaries, 2011-2013. Alzheimers Dement. 2017;13(1):28-37. 3
Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the
United States (2010-2050) estimated using the 2010 census.
Neurology. 2013;80(19):1778-1783. 4 Lewy Body Dementia Association
www.lbda.org.
Copyright 2020 by Tiburon Sunrise, LLC
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201014005922/en/
Lewy Body Dementia Association Angela Taylor (814) 826-4150
ataylor@lbda.org
Acadia Pharmaceuticals Inc. Eric Endicott (858) 914-7161
media@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Sep 2023 to Sep 2024